CAN ANTICANCER THERAPY BE IMPROVED BY SEQUENTIAL USE OF CYTO-TOXIC AND CYTOSTATIC (DIFFERENTIATING OR IMMUNOMODULATING) AGENTS TO SUPPRESS TUMOR-CELL PHENOTYPIC DIVERSIFICATION

被引：23

作者：

LOTAN, R

NICOLSON, GL

机构：

来源：

关键词：

D O I：

10.1016/0006-2952(88)90711-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：149 / 154

页数：6

共 69 条

[1]

BERTINO JR, 1983, CANCER TREAT REP, V67, P901

[2]

BIGLEY CG, 1987, INT J CANCER, V39, P99

[3]

BLOCH A, 1984, CANCER TREAT REP, V68, P199

[4]

BREGMAN MD, 1983, J NATN CANCER I, V71, P929

[5]

CARNEY DN, 1987, CANCER RES, V47, P821

[6]

CARTER SK, 1984, CANCER INVASION META, P397

[7] DIFFERENTIATING AGENTS IN THE TREATMENT OF HUMAN MALIGNANCIES [J].

CHESON, BD ;

JASPERSE, DM ;

CHUN, HG ;

FRIEDMAN, MA .

CHORAZY, M .

[9]

COHEN MH, 1972, J NATL CANCER I, V48, P921

[10]

FIDLER IJ, 1985, SEMIN ONCOL, V12, P207